EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cancer‐Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives

Ranran Shi iD, Ling Ran, Tiantian Song, Xiaowen Zhou, Wenshan Zhao iD, Yijie Zhang

Journal of Immunology Research · 2026

DOI: 10.1155/jimr/8131644 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, 2026. Verfasst von Ranran Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, Luohe Medical College, Luohe 462000, China, lhmc.edu.cn. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Neoplasms, Immunotherapy, Testis. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Doctoral Scientific Research Start-up Foundation of Luohe Medical College, Science and Technology Research Project of Henan Provincial Department of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer‐testis antigens (CTAs) represent a unique class of tumor‐associated antigens (TAAs) with highly restricted expression in immune‐privileged tissues and widespread aberrant activation in various malignancies. Their potent immunogenicity and tumor specificity make CTAs promising targets for cancer immunotherapy. This review provides a comprehensive overview of the molecular regulation, biological functions, and therapeutic applications of CTAs. We detail the genetic and epigenetic mechanisms that drive CTA expression in cancer, their roles in tumor progression, and their capacity to elicit robust CD8 + T cell responses. Recent clinical advances in peptide‐ and dendritic cell–based vaccines, T‐cell receptor (TCR)‐engineered adoptive cell therapies, and combination strategies with immune checkpoint inhibitors (ICIs) are highlighted, emphasizing NY‐ESO‐1 and MAGE family antigens as leading candidates. We further discuss the major challenges limiting clinical translation, emphasizing that despite promising immunogenicity, most CTA‐directed modalities remain in early clinical evaluation with heterogeneous response rates, intratumoral heterogeneity, antigen loss, and risks of off‐target toxicity. The review also explores emerging approaches—such as epigenetic modulators, multiantigen targeting, and CRISPR‐based gene editing—that aim to enhance the precision and efficacy of CTA‐based immunotherapies. Together, these insights underscore the strategic potential of CTAs in next‐generation immunotherapy and outline the future directions required to bring these promising agents from bench to bedside.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmNeoplasmsImmunotherapyTestisHumansCancer VaccinesAnimalsMaleEpigenesis, GeneticImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

antigen-specific vaccinescancer-testis antigens (CTAs)immune checkpoint inhibitorstumor heterogeneitytumor immunotherapy

Substanzen

Antigens, NeoplasmCancer VaccinesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Basic Medical Sciences, Luohe Medical College, Luohe 462000, China, lhmc.edu.cn.
  • Henan Province Engineering and Technology Research Center of Foods for Special Medical Purpose, Luohe Medical College, Luohe 462000, China, lhmc.edu.cn.
  • Respiratory Medicine Department, Luohe Central Hospital, Luohe 462000, China, lhzxyy.com.cn.
  • School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China, zzu.edu.cn.
  • Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng 475000, China, henu.edu.cn.

ORCID-Profile: Ranran Shi, Wenshan Zhao

Förderung

  • National Natural Science Foundation of China
  • Doctoral Scientific Research Start-up Foundation of Luohe Medical College
  • Science and Technology Research Project of Henan Provincial Department of Science and Technology
  • Key Research Projects of Higher Education Institutions in Henan Province
  • Luohe Medical College Science and Technology Innovation Project
  • Natural Science Foundation of Henan Province

Zitieren

APA

Shi, R., Ran, L., Song, T., Zhou, X., Zhao, W., & Zhang, Y. (2026). Cancer‐Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives. Journal of Immunology Research. https://doi.org/10.1155/jimr/8131644

Vancouver

Shi R, Ran L, Song T, Zhou X, Zhao W, Zhang Y. Cancer‐Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives. Journal of Immunology Research. 2026. doi:10.1155/jimr/8131644

BibTeX
@article{Shi2026,
  author = {Shi, Ranran and Ran, Ling and Song, Tiantian and Zhou, Xiaowen and Zhao, Wenshan and Zhang, Yijie},
  title = {Cancer‐Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives},
  journal = {Journal of Immunology Research},
  year = {2026},
  doi = {10.1155/jimr/8131644}
}
Kostenlos starten →